Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report

BACKGROUND: Hepatocellular carcinoma (HCC) with major portal vein tumor thrombus (Vp4 PVTT) is an extremely advanced tumor with limited treatment options. Systemic chemotherapy is the only recommended treatment option, and atezolizumab plus bevacizumab has recently emerged as a first-line treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Komatsu, Shohei, Fujishima, Yoshimi, Kido, Masahiro, Kuramitsu, Kaori, Goto, Tadahiro, Yanagimoto, Hiroaki, Toyama, Hirochika, Fukumoto, Takumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672589/
https://www.ncbi.nlm.nih.gov/pubmed/34911458
http://dx.doi.org/10.1186/s12876-021-02053-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672589/
https://www.ncbi.nlm.nih.gov/pubmed/34911458
http://dx.doi.org/10.1186/s12876-021-02053-4

Ejemplares similares